What the FDA labels say about taking them together
Ephedrine and iobenguane i 123
Iobenguane i 123's FDA label of January 10, 2024 names ephedrine in its drug interactions section; the ephedrine labels PlainMeds reads (4) do not name iobenguane i 123. The iobenguane i 123 label: “If the AdreView imaging information is essential for clinical care, consider the withdrawal of the following categories of medications if the withdrawal can be accomplished safely: antihypertensives that deplete …”
Check it at the source: the ephedrine FDA label on DailyMed (effective September 16, 2024, Nexus Pharmaceuticals, LLC); the iobenguane i 123 FDA label on DailyMed (effective January 10, 2024).
What does the ephedrine label say about iobenguane i 123?
Ephedrine's label (effective September 16, 2024) and its 3 other brand-application labels do not name iobenguane i 123 in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Emerphed PFS), Nexus Pharmaceuticals, LLC, effective September 16, 2024 (SPL set 14601778-93ac-43ec-b66b-5a942317133f), via openFDA; the full label on DailyMed
What does the iobenguane i 123 label say about ephedrine?
Iobenguane i 123 label, drug interactionsDRUG INTERACTIONS The following drugs have the potential to decrease the uptake of norepinephrine and cause false negative imaging results: antihypertensives that deplete norepinephrine stores or inhibit reuptake (e.g., reserpine, labetalol), antidepressants that inhibit norepinephrine transporter function (e.g., amitriptyline and derivatives, imipramine and derivatives, selective serotonin reuptake inhibitors), sympathomimetic amines (e.g., phenylephrine, phenylpropanolamine, pseudoephedrine and ephedrine), and cocaine.
Iobenguane i 123 label, warnings and precautionsIf the AdreView imaging information is essential for clinical care, consider the withdrawal of the following categories of medications if the withdrawal can be accomplished safely: antihypertensives that deplete norepinephrine stores or inhibit reuptake (e.g., reserpine, labetalol), antidepressants that inhibit norepinephrine transporter function (e.g., amitriptyline and derivatives, imipramine and derivatives, selective serotonin reuptake inhibitors), and sympathomimetic amines (e.g., phenylephrine, phenylpropanolamine, pseudoephedrine and ephedrine).
Source: FDA drug label (AdreView), Medi-Physics Inc., effective January 10, 2024 (SPL set c89d3ecc-4f4c-4566-8808-79152344194d), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Ephedrine | Iobenguane i 123 | |
|---|---|---|
| Labeled for | Asthma | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once